SELLAS Life Sciences Group, Inc.
General ticker "SLS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $130.3M (TTM average)
SELLAS Life Sciences Group, Inc. follows the US Stock Market performance with the rate: 32.7%.
Estimated limits based on current volatility of 6.8%: low 3.58$, high 4.11$
Factors to consider:
- Total employees count: 16 (-5.9%) as of 2023
- Top business risk factors: Liquidity and credit risks, Economic downturns and volatility, Geopolitical risks, Manufacturing risks, Cybersecurity threats
- Current price 280.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [0.48$, 1.55$]
- 2025-12-31 to 2026-12-31 estimated range: [0.31$, 1.04$]
Financial Metrics affecting the SLS estimates:
- Positive: with PPE of -1.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -6.13 <= 0.04
- Negative: negative Industry operating cash flow (median)
- Positive: 42.53 < Shareholder equity ratio, % of 48.71 <= 64.17
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Investing cash flow per share per price, % of 0 > -0.62
- Negative: negative Net income
Short-term SLS quotes
Long-term SLS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $1.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $42.95MM | $37.87MM | $31.51MM |
| Operating Income | $-41.95MM | $-37.87MM | $-31.51MM |
| Non-Operating Income | $0.65MM | $0.53MM | $0.63MM |
| R&D Expense | $20.27MM | $24.01MM | $19.10MM |
| Income(Loss) | $-41.30MM | $-37.34MM | $-30.88MM |
| Profit(Loss)* | $-41.30MM | $-37.34MM | $-30.88MM |
| Stockholders Equity | $4.85MM | $-7.98MM | $9.46MM |
| Assets | $20.94MM | $6.22MM | $19.43MM |
| Operating Cash Flow | $-23.81MM | $-31.41MM | $-35.40MM |
| Capital expenditure | $4.50MM | $5.50MM | $0.00MM |
| Investing Cash Flow | $-4.50MM | $-5.50MM | $0.00MM |
| Financing Cash Flow | $24.08MM | $22.32MM | $46.76MM |
| Earnings Per Share** | $-2.13 | $-0.15 | $-0.05 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.